title: Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells.
abstract: Cyclin D1 is over-expressed in various human tumors and therefore can be a potential oncogenic target antigen. However, only a limited number of T cell epitopes has been characterized. We aimed at identifying human cyclin D1-derived peptides that include both CD4 and CD8 T cell epitopes and to test if such multi-epitope peptides could yield improved cytotoxic CD8 T cell responses as well as cytotoxic CD4 T cells. Five HLA-DR.B1-binding peptides containing multiple overlapping CD4 epitopes and HLA-A0201-restricted CD8 T cell epitopes were predicted by computer algorithms. Immunogenicity of the synthetic peptides was assessed by stimulating T cells from healthy donors in vitro and the epitope recognition was measured by IFN-gamma ELISPOT and (51)Chromium release assays. A HLA-DR.B1 peptide, designed "DR-1", in which a HLA-A0201-binding epitopes (D1-1) was imbedded, induced CD3 T cell responses against both DR-1 and D1-1 peptides in IFN-gamma ELISPOT assay. This suggested processing of the shorter D1-1 epitope from the DR-1 sequence. However, only DR-1-stimulated CD4 or CD3 T cells possessed cytotoxicity against peptide-pulsed autologous DCs and a cancer cell line, that expresses a high level of cyclin D1. Monoclonal antibody to HLA-DR abrogated the epitope-specific responses of both CD3 and CD4 T cells, demonstrating class II-mediated killing. Our studies suggest a possible role of CD4 T cells in anti-tumor immunity as cytotoxic effectors against HLA-DR expressing cancers and provide a rationale for designing peptide vaccines that include CD4 epitopes.
authors.affiliation: Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
authors.forename: Tao
authors.initials: T
authors.lastname: Dao
authors.forename: Tatyana
authors.initials: T
authors.lastname: Korontsvit
authors.forename: Victoria
authors.initials: V
authors.lastname: Zakhaleva
authors.forename: Kurtis
authors.initials: K
authors.lastname: Haro
authors.forename: Jonathan
authors.initials: J
authors.lastname: Packin
authors.forename: David A
authors.initials: DA
authors.lastname: Scheinberg
mesh_terms: D000595:Amino Acid Sequence; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000187:drug effects* / Q000276:immunology; D045744:Cell Line, Tumor; D019938:Cyclin D1 / Q000737:chemistry / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D006801:Humans; D008969:Molecular Sequence Data; D010455:Peptides / Q000737:chemistry / Q000494:pharmacology*; D010641:Phenotype; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology / Q000187:drug effects* / Q000276:immunology
chemical_list: D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D010455:Peptides; D019938:Cyclin D1
references.citation: J Immunol. 2007 Oct 15;179(8):5033-40
references.pmid: 17911588
references.citation: Cancer Immunol Immunother. 2004 Oct;53(10):904-10
references.pmid: 15069585
references.citation: Oncogene. 2006 Feb 16;25(7):998-1007
references.pmid: 16247460
references.citation: J Exp Med. 2000 Jul 3;192(1):145-50
references.pmid: 10880536
references.citation: Immunity. 2000 Oct;13(4):529-38
references.pmid: 11070171
references.citation: J Cell Biochem. 2005 Dec 1;96(5):906-13
references.pmid: 16163738
references.citation: Nat Rev Cancer. 2008 May;8(5):351-60
references.pmid: 18418403
references.citation: Oncogene. 2006 Mar 13;25(11):1620-8
references.pmid: 16550162
references.citation: J Exp Med. 1998 Dec 21;188(12):2357-68
references.pmid: 9858522
references.citation: Cancer Res. 2003 Nov 1;63(21):7056-61
references.pmid: 14612495
references.citation: Clin Cancer Res. 2006 Dec 15;12(24):7476-82
references.pmid: 17189421
references.citation: Eur J Immunol. 1998 Jan;28(1):193-200
references.pmid: 9485199
references.citation: Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14639-45
references.pmid: 15381769
references.citation: N Engl J Med. 2008 Jun 19;358(25):2698-703
references.pmid: 18565862
references.citation: Eur J Immunol. 2004 Dec;34(12):3644-51
references.pmid: 15495271
references.citation: Nat Med. 2004 Sep;10(9):909-15
references.pmid: 15340416
references.citation: J Biol Chem. 2003 Aug 8;278(32):30339-47
references.pmid: 12746453
references.citation: Nat Immunol. 2004 Sep;5(9):927-33
references.pmid: 15300249
references.citation: Blood. 2007 Jun 15;109(12):5346-54
references.pmid: 17327412
references.citation: J Exp Med. 2005 Oct 17;202(8):1109-19
references.pmid: 16216889
references.citation: J Clin Invest. 2005 Dec;115(12):3623-33
references.pmid: 16308572
references.citation: Nat Rev Cancer. 2007 Nov;7(11):880-7
references.pmid: 17957190
references.citation: Leuk Res. 2006 Oct;30(10):1293-8
references.pmid: 16533527
references.citation: J Immunol. 2006 May 15;176(10):6340-6
references.pmid: 16670346
references.citation: Annu Rev Immunol. 2006;24:519-40
references.pmid: 16551258
references.citation: Lung Cancer. 2007 Jan;55(1):1-14
references.pmid: 17070615
references.citation: Cancer Res. 1999 Jul 1;59(13):3128-33
references.pmid: 10397255
references.citation: Cell Mol Life Sci. 2003 Jul;60(7):1296-310
references.pmid: 12943219
references.citation: Cancer Biol Ther. 2002 May-Jun;1(3):226-31
references.pmid: 12432268
references.citation: Adv Drug Deliv Rev. 2006 Oct 1;58(8):916-30
references.pmid: 16979788
references.citation: J Exp Med. 2006 Apr 17;203(4):805-8
references.pmid: 16549599
references.citation: J Immunol. 2000 Dec 1;165(11):6047-55
references.pmid: 11086036
references.citation: Blood. 2006 Nov 1;108(9):3121-7
references.pmid: 16840731
references.citation: Nature. 2003 Feb 20;421(6925):852-6
references.pmid: 12594515
references.citation: Cancer Lett. 1997 Feb 26;113(1-2):123-30
references.pmid: 9065811
references.citation: Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4547-55
references.pmid: 17671141
references.citation: J Immunol. 2008 Dec 1;181(11):7445-8
references.pmid: 19017930
references.citation: Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8347-50
references.pmid: 1518868
references.citation: Clin Cancer Res. 2008 Oct 15;14(20):6574-9
references.pmid: 18927298
references.citation: Haematologica. 2005 Oct;90(10):1324-32
references.pmid: 16219568
references.citation: Science. 2003 Apr 11;300(5617):337-9
references.pmid: 12690201
references.citation: Nature. 1998 Jun 4;393(6684):480-3
references.pmid: 9624005
references.citation: J Immunol. 1998 Oct 15;161(8):4023-32
references.pmid: 9780172
references.citation: Blood. 2008 Feb 1;111(3):1404-12
references.pmid: 17986662
references.citation: Blood. 2006 Sep 1;108(5):1744-50
references.pmid: 16690963